Cancer Chemotherapy and Pharmacology

, Volume 82, Issue 6, pp 935–943 | Cite as

Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

  • Joan Maurel
  • Santiago Sánchez-Cabús
  • Berta Laquente
  • Lydia Gaba
  • Laura Visa
  • Joan Fabregat
  • Ignacio Povés
  • Susana Roselló
  • Roberto Díaz-Beveridge
  • Marta Martín-Richard
  • Javier Rodriguez
  • Luis Sabater
  • Carles Conill
  • María Cambray
  • Ana Reig
  • Juan Ramón Ayuso
  • Carlos Valls
  • Antonio Ferrández
  • Josep Antoni Bombí
  • Angels Ginés
  • Xabier García-Albéniz
  • Laureano Fernández-Cruz
Original Article



Neoadjuvant therapy (NAT) for pancreatic adenocarcinoma (PDAC) patients has shown promising results in non-randomized trials. This is a multi-institutional phase II trial of NAT in resectable PDAC patients.


Patients with confirmed resectable PDAC after agreement by two expert radiologists were eligible. Patients received three cycles of GEM (1000 mg/m2/week) plus daily erlotinib (ERL) (100 mg/day). After re-staging, patients without progressive disease underwent 5 weeks of therapy with GEM (300 mg/m2/week), ERL 100 mg/day and concomitant radiotherapy (45 Gy). Efficacy was assessed using tumor regression grade (TRG) and resection margin status. Using a single-arm Simon’s design, considering the therapy not useful if R0 < 40% and useful if the R0 > 70% (alpha 5%, beta 10%), 24 patients needed to be recruited. This trial was registered at, number NCT01389440.


Twenty-five patients were enrolled. Adverse effects of NAT were mainly mild gastrointestinal disorders. Resectability rate was 76%, with a R0 rate of 63.1% among the resected patients. Median overall survival (OS) and disease-free survival (DFS) were 23.8 (95% CI 11.4–36.2) and 12.8 months (95% CI 8.6–17.1), respectively. R0 resection patients had better median OS, compared with patients with R1 resection or not resected (65.5 months vs. 15.5 months, p = 0.01). N0 rate among the resected patients was 63.1%, and showed a longer median OS (65.5 vs. 15.2 months, p = 0.009).


The results of this study confirm promising oncologic results with NAT for patients with resectable PDAC. Therefore, the present trial supports the development of phase II randomized trials comparing NAT vs. upfront surgery in resectable pancreatic cancer.


Neoadjuant Pancreatic Adenocarcinoma 




Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study are in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Varadhachary GR, Wolff RA, Crane CH et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487–3495CrossRefGoogle Scholar
  2. 2.
    OʼReilly EM, Perelshteyn A, Jarnagin WR et al (2014) A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 260:142–148CrossRefGoogle Scholar
  3. 3.
    Heinrich S, Schäfer M, Weber A et al (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248:1014–1022CrossRefGoogle Scholar
  4. 4.
    White RR, Hurwitz HI, Morse MA et al (2001) Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 8:758–765CrossRefGoogle Scholar
  5. 5.
    Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89:314–327CrossRefGoogle Scholar
  6. 6.
    Talamonti MS, Small W, Mulcahy MF et al (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150–158CrossRefGoogle Scholar
  7. 7.
    Pipas JM, Barth RJ, Zaki B et al (2005) Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12:995–1004CrossRefGoogle Scholar
  8. 8.
    Golcher H, Brunner TB, Witzigmann H et al (2015) Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 191:7–16CrossRefGoogle Scholar
  9. 9.
    Evans DB, Varadhachary GR, Crane CH et al (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496–3502CrossRefGoogle Scholar
  10. 10.
    Joensuu TK, Kiviluoto T, Kärkkäinen P et al (2004) Phase I–II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60:444–452CrossRefGoogle Scholar
  11. 11.
    Duffy A, Kortmansky J, Schwartz GK et al (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol Off J Eur Soc Med Oncol 19:86–91CrossRefGoogle Scholar
  12. 12.
    Maurel J, Martin-Richard M, Conill C et al (2006) Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 66:1391–1398CrossRefGoogle Scholar
  13. 13.
    Gómez-Mateo MDC, Sabater-Ortí L, Ferrández-Izquierdo A (2014) Pathology handling of pancreatoduodenectomy specimens: approaches and controversies. World J Gastrointest Oncol 6:351–359CrossRefGoogle Scholar
  14. 14.
    Esposito I, Kleeff J, Bergmann F et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660CrossRefGoogle Scholar
  15. 15.
    Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathol Correl Cancer 73:2680–2686Google Scholar
  16. 16.
    Xia BT, Fu B, Wang J et al (2017) Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol 115:376–383CrossRefGoogle Scholar
  17. 17.
    Youngwirth LM, Nussbaum DP, Thomas S et al (2017) Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18243 patients. J Surg Oncol 116:127–132CrossRefGoogle Scholar
  18. 18.
    Mirkin KA, Hollenbeak CS, Wong J (2016) Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. Int J Surg 34:96–102CrossRefGoogle Scholar
  19. 19.
    Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G (2016) Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer—a case report and review. BMC Cancer 16:786CrossRefGoogle Scholar
  20. 20.
    Hackert T, Sachsenmaier M, Hinz U et al (2016) Locally advanced pancreatic cancer—neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg 264:1CrossRefGoogle Scholar
  21. 21.
    Blaze M, Wu C, Goldberg RM et al (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22:1153–1159CrossRefGoogle Scholar
  22. 22.
    Petrelli F, Coinu A, Borgonovo K et al (2015) FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 44:515–521CrossRefGoogle Scholar
  23. 23.
    Lee JH, Kang CM, Bang SM et al (2015) The role of neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic cancer with isolated venous vascular involvement. Medicine (Baltimore) 94:e1233CrossRefGoogle Scholar
  24. 24.
    Schneitler S, Kröpil P, Riemer J et al (2015) Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World J Gastroenterol 21:6384–6390CrossRefGoogle Scholar
  25. 25.
    Miura JT, Krepline AN, George B et al (2015) Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery 158:1545–1555CrossRefGoogle Scholar
  26. 26.
    Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317–323CrossRefGoogle Scholar
  27. 27.
    Youngwirth LM, Nussbaum DP, Thomas S et al (2017) Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18,243 patients. J Surg Oncol 116:127–132CrossRefGoogle Scholar
  28. 28.
    Shubert CR, Bergquist JR, Groeschl RT et al (2016) Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database. Surgery (United States) 160:1080–1096Google Scholar
  29. 29.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277CrossRefGoogle Scholar
  30. 30.
    Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. JAMA 304:1073CrossRefGoogle Scholar
  31. 31.
    Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024CrossRefGoogle Scholar
  32. 32.
    O’Reilly EM, Perelshteyn A, Jarnagin WR et al (2014) A single-arm, non-randomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 260:142–148CrossRefGoogle Scholar
  33. 33.
    Mokdad AA, Minter RM, Zhu H et al (2017) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35:515–522CrossRefGoogle Scholar
  34. 34.
    D’Angelo FA, Antolino L, La Rocca M et al (2016) Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials. Med Oncol 33:1–9CrossRefGoogle Scholar
  35. 35.
    Katz MHG, Shi Q, Ahmad SA et al (2016) Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg 151:e161137CrossRefGoogle Scholar
  36. 36.
    Hammel P, Huguet F, van Laethem J-L et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853CrossRefGoogle Scholar
  37. 37.
    Collisson EA, Sadanandam A, Olson P et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17:500–503CrossRefGoogle Scholar
  38. 38.
    Feig C, Jones JO, Kraman M et al (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110:20212–20217CrossRefGoogle Scholar
  39. 39.
    Gunderson AJ, Kaneda MM, Tsujikawa T et al (2016) Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 6:270–285CrossRefGoogle Scholar
  40. 40.
    Mace TA, Ameen Z, Collins A et al (2013) Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73:3007–3018CrossRefGoogle Scholar
  41. 41.
    Steele CW, Karim SA, Leach JDG et al (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29:832–845CrossRefGoogle Scholar
  42. 42.
    Yang X, Lin Y, Shi Y et al (2016) FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res 76:4124–4135CrossRefGoogle Scholar
  43. 43.
    Kalbasi A, Komar C, Tooker GM et al (2017) Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res 23:137–148CrossRefGoogle Scholar
  44. 44.
    Mitchem JB, Brennan DJ, Knolhoff BL et al (2013) Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 73:1128–1141CrossRefGoogle Scholar
  45. 45.
    Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP (2010) CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 103:1671–1679CrossRefGoogle Scholar
  46. 46.
    Nywening TM, Wang-Gillam A, Sanford DE et al (2016) Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651–662CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Joan Maurel
    • 3
  • Santiago Sánchez-Cabús
    • 1
  • Berta Laquente
    • 2
  • Lydia Gaba
    • 3
  • Laura Visa
    • 4
  • Joan Fabregat
    • 5
  • Ignacio Povés
    • 6
  • Susana Roselló
    • 7
  • Roberto Díaz-Beveridge
    • 8
  • Marta Martín-Richard
    • 9
  • Javier Rodriguez
    • 10
  • Luis Sabater
    • 11
  • Carles Conill
    • 12
  • María Cambray
    • 13
  • Ana Reig
    • 14
  • Juan Ramón Ayuso
    • 15
  • Carlos Valls
    • 16
  • Antonio Ferrández
    • 17
  • Josep Antoni Bombí
    • 18
  • Angels Ginés
    • 19
  • Xabier García-Albéniz
    • 20
  • Laureano Fernández-Cruz
    • 1
  1. 1.Surgical Department, Hospital Clínic BarcelonaIDIBAPS, University of BarcelonaBarcelonaSpain
  2. 2.Medical Oncology DepartmentInstitut Català d’OncologiaHospitaletSpain
  3. 3.Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors GroupIDIBAPS, University of BarcelonaBarcelonaSpain
  4. 4.Department of OncologyHospital MarBarcelonaSpain
  5. 5.Surgical DepartmentHospital BellvitgeHospitaletSpain
  6. 6.Surgical DepartmentHospital del MarBarcelonaSpain
  7. 7.Medical Oncology DepartmentHospital Clínico ValenciaValenciaSpain
  8. 8.Medical Oncology DepartmentHospital La FeValenciaSpain
  9. 9.Medical Oncology DepartmentHospital Sant PauBarcelonaSpain
  10. 10.Medical Oncology DepartmentHospital Clínico Universitario NavarraPamplonaSpain
  11. 11.Surgical DepartmentHospital Clínico ValenciaValenciaSpain
  12. 12.Radiotherapy Oncology Department, Hospital Clínic BarcelonaIDIBAPS, University of BarcelonaBarcelonaSpain
  13. 13.Radiotherapy Oncology DepartmentInstitut Català d’OncologiaHospitaletSpain
  14. 14.Radiotherapy Oncology DepartmentHospital MarBarcelonaSpain
  15. 15.Radiology Department, Hospital Clínic BarcelonaIDIBAPS, University of BarcelonaBarcelonaSpain
  16. 16.Radiology DepartmentHospital BellvitgeHospitaletSpain
  17. 17.Pathology DepartmentHospital Clínico ValenciaValenciaSpain
  18. 18.Pathology Department, Hospital Clínic BarcelonaIDIBAPS, University of BarcelonaBarcelonaSpain
  19. 19.Gastrointestinal Department, Hospital Clínic BarcelonaIDIBAPS, University of BarcelonaBarcelonaSpain
  20. 20.Harvard T.H. Chan School of Public HealthBostonUSA

Personalised recommendations